tradingkey.logo

Viatris Inc

VTRS
查看詳細走勢圖
11.930USD
-0.010-0.08%
收盤 12/19, 16:00美東報價延遲15分鐘
13.83B總市值
虧損本益比TTM

Viatris Inc

11.930
-0.010-0.08%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.08%

5天

+2.40%

1月

+17.08%

6月

+34.50%

今年開始到現在

-4.18%

1年

-4.71%

查看詳細走勢圖

TradingKey Viatris Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Viatris Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名32/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價12.46。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Viatris Inc評分

相關信息

行業排名
32 / 158
全市場排名
85 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 12 分析師
持有
評級
12.457
目標均價
+12.32%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Viatris Inc亮點

亮點風險
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
業績轉虧
公司業績轉虧,最新年度虧損美元
估值合理
公司最新PE估值-3.81,處於3年歷史合理位
機構減倉
最新機構持股987.12M股,環比減少4.49%
Mairs and Power 公司持倉
明星投資者Mairs and Power 公司持倉,最新持倉10.54K股

Viatris Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Viatris Inc簡介

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
公司代碼VTRS
公司Viatris Inc
CEOSmith (Scott A)
網址https://www.viatris.com/en

常見問題

Viatris Inc(VTRS)的當前股價是多少?

Viatris Inc(VTRS)的當前股價是 11.930。

Viatris Inc 的股票代碼是什麼?

Viatris Inc的股票代碼是VTRS。

Viatris Inc股票的52週最高點是多少?

Viatris Inc股票的52週最高點是12.680。

Viatris Inc股票的52週最低點是多少?

Viatris Inc股票的52週最低點是6.850。

Viatris Inc的市值是多少?

Viatris Inc的市值是13.83B。

Viatris Inc的淨利潤是多少?

Viatris Inc的淨利潤為-634.20M。

現在Viatris Inc(VTRS)的股票是買入、持有還是賣出?

根據分析師評級,Viatris Inc(VTRS)的總體評級為持有,目標價格為12.457。

Viatris Inc(VTRS)股票的每股收益(EPS TTM)是多少

Viatris Inc(VTRS)股票的每股收益(EPS TTM)是-3.131。
KeyAI